Advertisement

Progression in smoldering Waldenström macroglobulinemia: long-term results

Robert A. Kyle, Joanne T. Benson, Dirk R. Larson, Terry M. Therneau, Angela Dispenzieri, Shaji Kumar, L. Joseph Melton III and S. Vincent Rajkumar

Article Figures & Data

Figures

Tables

  • Table 1

    Clinical and laboratory features among 48 patients with SWM

    Progression to WM (N = 34)Nonprogression (N = 12)Total (N = 48)Comments
    Male (%)6583
    Age at diagnosis, y
        Median626563Only 1 person < 40 y
        Range39-87
    Liver palpable, N*41
    Spleen palpable, N*11
    Lymphadenopathy, N*40
    Hemoglobin, g/dL
        Median11.412.811.8< 10 g/dL in 8%
        Range8.7-14.18.7-15.38.7-15.3< 12 g/dL in 54%
    Serum monoclonal protein, g/dL
        Median3.43.03.3< 3 g dL in 25%
        Range1.5-5.21.8-4.01.5-5.2≥ 4 g/dL in 21%
    Serum creatinine, mg/dL
        Median1.11.11.1> 2 mg/dL in 2% (missing in 2)
        Range.6-2.1.7-1.4.6-2.1
    β2-microglobulin, μg/mL≤ 1.8 μg/mL in 4
        Median2.12.22.14≥ 3 μg/mL in 3 (missing in 26)
        Range1.6-4.01.5-3.21.5-4.0
    Urine monoclonal protein, g/24 hours< 0.1 g/24 h in 70%
        Median.1.05> 0.2 g/24 h in 17%
        RangeNot measurable to 1.4Not measurable to 0.3Not measurable to 1.4> 1.0 g/24 h in 3% (missing in 18)
    Bone marrow lymphoplasmacytic cells, %
        Median401530≥ 10% in 94%
        Range8-803-303-80≥ 50% in 27%
    • * Information not available on 7 patients.

  • Table 2

    Risk factors for progression to treatment among 48 patients with SWM

    Multivariate modelHazard ratioP
    Bone marrow lymphoplasmacytic cells1.31 (1.1-1.5)< .001
    Hemoglobin value0.7 (0.5-0.9).002
    Serum M protein value2.1 (1.3-3.5).003
    IgA reduction2.4 (1.1-5.4).036